Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
West Pharmaceutical Services (WST) stock has drawn attention after recent share price moves, with investors weighing its role in drug containment and delivery in relation to current valuation signals and recent returns over the past month and past 3 months.
See our latest analysis for West Pharmaceutical Services.
At a share price of $327.95, West Pharmaceutical Services has seen strong momentum build over the past quarter, with a 35.85% 3 month share price return and a 52.46% 1 year total shareholder return, even though the 3 year total shareholder return is down 9.89%.
If recent moves in West Pharmaceutical Services have you looking beyond a single stock, it could be a good time to broaden your search with 40 healthcare AI stocks.
So, with West Pharmaceutical Services trading near recent highs after strong 1-year returns, is the stock still undervalued based on its fundamentals, or has the market already priced in much of its future growth potential?
Most Popular Narrative: 6.9% Undervalued
With West Pharmaceutical Services last closing at $327.95 against a narrative fair value of $352.36, the current setup hinges on how durable its high value injectable exposure really is.
The continued growth in GLP-1s, which made up about 7% of total revenues in the first quarter, and the company’s ability to capitalize on significant opportunities in this market could drive revenue and earnings growth. The increase in demand and the transition to higher-margin HVP components, supported by approximately 340 Annex 1 projects, is likely to positively impact both revenue and net margins due to a favorable mix shift.
Want to see what sits behind that confidence in GLP 1s and high value components? The narrative leans on steady revenue expansion, wider margins, and a premium earnings multiple that assumes the product mix keeps tilting toward these higher value platforms.
Result: Fair Value of $352.36 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, there are still real pressure points for West Pharmaceutical Services, including HVP capacity constraints and tariff or pricing risks that could weaken the bullish narrative.
Find out about the key risks to this West Pharmaceutical Services narrative.
Another View: What Multiples Say About West Pharmaceutical Services
While the latest narrative suggests West Pharmaceutical Services is about 6.9% undervalued against a $352.36 fair value, its current P/E of 42.7x tells a different story. That is higher than the peer average of 38.2x, the global Life Sciences average of 34.3x, and the fair ratio of 21.3x, which the market could also move toward over time. For investors, that gap points to valuation risk if sentiment cools, so the key question is whether West Pharmaceutical Services can keep justifying this premium.
For a closer look at how this earnings multiple stacks up and what it could mean for future pricing power, See what the numbers say about this price — find out in our valuation breakdown.
NYSE:WST P/E Ratio as at Jun 2026 Next Steps
Given the mixed messages on valuation and sentiment around West Pharmaceutical Services, this may be a good moment to review the numbers yourself and decide where you stand. To see what optimistic investors are focusing on, take a closer look at the company’s 2 key rewards
Looking for more investment ideas beyond West Pharmaceutical Services?
If you stop with West Pharmaceutical Services, you could miss opportunities that better fit your goals, so consider widening your search with a few targeted stock ideas.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include WST.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com